DEA Moves to Ban 7-Hydroxymitragynine Above Certain Threshold
Published Date: 7/6/2026
Proposed Rule
Summary
Starting July 6, 2026, the DEA plans to temporarily put 7-hydroxymitragynine above a certain amount into Schedule I, meaning it’s treated like the most tightly controlled drugs. This affects anyone who makes, sells, studies, or even just has this substance, bringing strict rules and penalties. The move aims to keep people safe while the government figures out the long-term plan.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
Temporary Schedule I Placement
If you make, sell, import, study, or possess 7-hydroxymitragynine above the specified threshold, it will be treated as a Schedule I controlled substance starting on the date the temporary order is published in the Federal Register (on or after August 5, 2026). That means Schedule I regulatory controls plus administrative, civil, and criminal sanctions will apply to manufacturing, distribution, import/export, research, instructional activities, chemical analysis, reverse distribution, and possession.
Which Products Meet the Threshold
The temporary order covers: (A) any Mitragyna speciosa botanical material that contains more than 0.050% 7-hydroxymitragynine on a dry weight basis; and (B) any synthetic or processed article that contains more than 0.050% (w/w, w/v, or v/v) or more than 1.00 milligram of 7-hydroxymitragynine in the article. The record shows commercial products vary from about 1 mg to 700 mg per dose (average cost about $3.97 per dose), so many extracts, concentrates, tablets, gummies, and similar formulations could be covered when the order takes effect.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20226, By Grace Inc. Counseling Services; Decision and Order
By Grace Inc. Counseling Services in Baltimore faced losing its DEA license because it didn’t keep good records and lied about its owner’s past drug conviction. After a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle controlled substances anymore. This affects the clinic’s ability to operate and could impact patients relying on their services.
2026-20227, St. Michael's Pharmacy; Decision and Order
St. Michael's Pharmacy in Texas had its DEA license suspended and is facing revocation because it kept filling risky drug prescriptions without fixing obvious warning signs of abuse. This affects the pharmacy’s ability to legally handle controlled substances and could impact patients relying on it. The pharmacy must now deal with these serious legal actions, which started in late 2025 and could lead to permanent closure or fines.
Previous / Next Documents
Previous: 2026-13557, Receipt of Pesticide Petitions Filed for Residues of Pesticide Chemicals in or on Various Commodities-April 2026
The EPA just announced new requests to change rules about pesticide leftovers on foods like fruits and veggies. Farmers, food makers, and shoppers should pay attention because these changes could affect what’s allowed on your food. You’ve got until August 5, 2026, to share your thoughts before the EPA makes decisions that might impact food safety and farming costs.
Next: 2026-13581, Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I
Starting July 6, 2026, the DEA plans to temporarily put three substances related to 7-hydroxymitragynine—Mitragynine Pseudoindoxyl, MGM-15, and MGM-16—into Schedule I, the strictest drug category. This means anyone making, selling, or using these chemicals will face tough legal rules and penalties. The move aims to control these substances quickly while the DEA studies them further, affecting businesses and researchers handling these compounds.